UPDATE : Friday, June 14, 2019
상단여백
KangStem Biotech completes stem cell drug plant by Jeong Sae-im 2019-05-16 11:27
Samsung BioLogics in tight spot amid probe, shareholders’ lawsuit by Jeong Sae-im 2019-05-14 14:10
Celltrion’s operating income down 33% in Q1 by Jeong Sae-im 2019-05-09 15:26
If Invossa license gets revoked, Kolon should return $13 million to Mundipharma by Jeong Sae-im 2019-05-08 15:33
Inspection will clear all suspicions over Invossa: TissueGene by Jeong Sae-im 2019-05-08 14:32
라인
Kolon might have covered up Invossa mislabeling for 2 years by Jeong Sae-im 2019-05-07 15:55
When will regulator visit Kolon TissueGene for inspection? by Lee Hye-seon 2019-05-02 14:09
Civic group files complaint against Kolon, regulator by Jeong Sae-im 2019-04-30 14:59
FDA OKs Celltrion’s antibiotics generic by Lee Han-soo 2019-04-30 11:22
Huons, Genexine to cooperate on biopharmaceuticals by Lee Han-soo 2019-04-29 15:10
라인
Techniques for biobetters get ever more advanced by Jeong Sae-im 2019-04-29 11:48
Prosecutors seek arrest warrant of Samsung Bioepis executives by Lee Han-soo 2019-04-26 17:19
FDA OKs Samsung Bioepis’ Etanercept biosimilar by Lee Han-soo 2019-04-26 14:22
Foreign patients to join class-action suit against Kolon for Invossa by Jeong Sae-im 2019-04-25 15:39
Samsung Bioepis’ biosimilar sales in EU topped $170 million in Q1 by Lee Han-soo 2019-04-25 14:07
라인
Samsung Biologics logs ₩23.4 billion operating loss in Q1 by Jeong Sae-im 2019-04-25 12:08
OECD guideline OKs Korean-developed eye irritation test by Lee Hye-seon 2019-04-22 15:33
Gene therapies’ potentials, challenges explained by Jeong Sae-im 2019-04-22 11:46
Why is TissueGene CEO silent about Invossa mislabeling? by Jeong Sae-im 2019-04-19 14:37
‘How Korean pharma companies can succeed in US’ by Lee Han-soo 2019-04-18 14:41
여백
여백
여백
Back to Top